Founded in 2007, we are a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases. From GenHunter, we in-licensed the Trimer-Tag™ technology platform, a product development platform for the creation of novel vaccines and biologic therapies. Our product pipeline consists of six Trimer-Tag™ subunit vaccine candidates, two Trimer-Tag™ oncology product candidates, and three Fc-fusion product candidates.
We have leveraged the Trimer-Tag™ technology platform to become a COVID-19 vaccine developer and created SCB-2019 (CpG 1018/Alum) to address the COVID-19 pandemic caused by SARS-CoV-2. We will potentially become one of the first companies to commercialize a protein-based COVID-19 vaccine globally through the COVAX Facility.
Data Provided by Refinitiv. Minimum 15 minutes delayed.